Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael A Carducci

Showing results (81-90 of 322) with videos related to

Pageof 33
Sort By:
BJU International|February 18, 2014
Association of pretreatment neutrophil-to-lymphocyte ratio (NLR) and overall survival (OS) in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with first-line docetaxelPhilipp Nuhn, Ajay M Vaghasia, Jatinder Goyal, et al.
European Urology|February 5, 2014
The influence of prior abiraterone treatment on the clinical activity of docetaxel in men with metastatic castration-resistant prostate cancerMichael T Schweizer, Xian C Zhou, Hao Wang, et al.
Neuro-Oncology|April 16, 2005
Oral sodium phenylbutyrate in patients with recurrent malignant gliomas: a dose escalation and pharmacologic studySurasak Phuphanich, Sharyn D Baker, Stuart A Grossman, et al.
The Prostate|December 22, 2024
Association of SGLT2 Inhibitor Initiation and PSA Response in Prostate CancerEtan R Aber, Michael A Carducci, Channing J Paller, et al.
Cancer Research|September 5, 2006
Class II histone deacetylases are associated with VHL-independent regulation of hypoxia-inducible factor 1 alphaDavid Z Qian, Sushant K Kachhap, Spencer J Collis, et al.
European Journal of Cancer (Oxford, England : 1990)|May 24, 2011
Angiotensin system inhibitors and outcome of sunitinib treatment in patients with metastatic renal cell carcinoma: a retrospective examinationDaniel Keizman, Peng Huang, Mario A Eisenberger, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 1, 2007
Prostate-specific antigen and pain surrogacy analysis in metastatic hormone-refractory prostate cancerAndrew J Armstrong, Elizabeth Garrett-Mayer, Yi-Chun Ou Yang, et al.
Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation|March 28, 2013
Using the EORTC-QLQ-C30 in clinical practice for patient management: identifying scores requiring a clinician's attentionClaire F Snyder, Amanda L Blackford, Toru Okuyama, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 27, 2005
Pharmacokinetics of 5-azacitidine administered with phenylbutyrate in patients with refractory solid tumors or hematologic malignanciesMichelle A Rudek, Ming Zhao, Ping He, et al.
Journal of Cancer Survivorship : Research and Practice|May 10, 2011
Preventive care in prostate cancer patients: following diagnosis and for five-year survivorsClaire F Snyder, Kevin D Frick, Robert J Herbert, et al.
Pageof 33

Showing results (81-90 of 322) with videos related to

Sort By:
Pageof 33
BJU International|February 18, 2014
Association of pretreatment neutrophil-to-lymphocyte ratio (NLR) and overall survival (OS) in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with first-line docetaxelPhilipp Nuhn, Ajay M Vaghasia, Jatinder Goyal, et al.
European Urology|February 5, 2014
The influence of prior abiraterone treatment on the clinical activity of docetaxel in men with metastatic castration-resistant prostate cancerMichael T Schweizer, Xian C Zhou, Hao Wang, et al.
Neuro-Oncology|April 16, 2005
Oral sodium phenylbutyrate in patients with recurrent malignant gliomas: a dose escalation and pharmacologic studySurasak Phuphanich, Sharyn D Baker, Stuart A Grossman, et al.
The Prostate|December 22, 2024
Association of SGLT2 Inhibitor Initiation and PSA Response in Prostate CancerEtan R Aber, Michael A Carducci, Channing J Paller, et al.
Cancer Research|September 5, 2006
Class II histone deacetylases are associated with VHL-independent regulation of hypoxia-inducible factor 1 alphaDavid Z Qian, Sushant K Kachhap, Spencer J Collis, et al.
European Journal of Cancer (Oxford, England : 1990)|May 24, 2011
Angiotensin system inhibitors and outcome of sunitinib treatment in patients with metastatic renal cell carcinoma: a retrospective examinationDaniel Keizman, Peng Huang, Mario A Eisenberger, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 1, 2007
Prostate-specific antigen and pain surrogacy analysis in metastatic hormone-refractory prostate cancerAndrew J Armstrong, Elizabeth Garrett-Mayer, Yi-Chun Ou Yang, et al.
Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation|March 28, 2013
Using the EORTC-QLQ-C30 in clinical practice for patient management: identifying scores requiring a clinician's attentionClaire F Snyder, Amanda L Blackford, Toru Okuyama, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 27, 2005
Pharmacokinetics of 5-azacitidine administered with phenylbutyrate in patients with refractory solid tumors or hematologic malignanciesMichelle A Rudek, Ming Zhao, Ping He, et al.
Journal of Cancer Survivorship : Research and Practice|May 10, 2011
Preventive care in prostate cancer patients: following diagnosis and for five-year survivorsClaire F Snyder, Kevin D Frick, Robert J Herbert, et al.
Pageof 33